MIRM vs RARE
MIRM: Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic liver disease and viral hepatitis. RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
Side-by-side fundamentals
| Metric | MIRM | RARE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $114.48 | $27.65 | |
| Market cap as of 2026-07-23 | $7.0B | $2.8B | |
| PEG as of 2026-07-23 | -0.01 | -1.23 | RARE lower |
| Net margin as of 2026-07-23 | -140.2% | -91.0% | RARE higher |
| Gross margin as of 2026-07-23 | +81.4% | +83.6% | RARE higher |
| Operating margin as of 2026-07-23 | -139.8% | -83.8% | RARE higher |
| ROE as of 2026-07-23 | -289.3% | -414.2% | MIRM higher |
| ROA as of 2026-07-23 | -98.5% | -45.7% | RARE higher |
| Debt / equity as of 2026-07-23 | 1.28 | 90.54 | MIRM lower |
| Revenue growth (YoY) as of 2026-07-23 | +50.2% | +13.3% | MIRM higher |
| Revenue CAGR (3y) SEC XBRL | +89.1% | +22.8% | MIRM higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.51 | 0.28 | |
| 1-year return as of 2026-07-22 close | +119.4% | +4.6% | MIRM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.